Skip to content

REGEN BIOPHARMA, INC.: 10-Q filed 2025-05-28

What REGEN BIOPHARMA, INC. reported in its quarterly report filed 2025-05-28 (fiscal Q2 2025): 31 published measures, 87 facts as tagged in accession 0001641172-25-012619.

This filing

Form
10-Q (quarterly report)
Filed
2025-05-28
Fiscal period
fiscal Q2 2025
Accession
0001641172-25-012619 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REGEN BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-03-31169,482USD
At 2024-09-30161,084USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-03-315,867,880USD
At 2024-09-305,378,456USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-03-31-5,698,399USD
At 2024-09-30-5,217,372USD
At 2024-03-31-5,175,963USD
At 2023-09-30-5,103,999USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-19,354USD90
2024-10-01 to 2025-03-31-534,739USD182
2024-01-01 to 2024-03-31-122,454USD91
2023-10-01 to 2024-03-31-267,387USD183

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-10-01 to 2025-03-31-167,609USD182
2023-10-01 to 2024-03-31-371,658USD183

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2025-01-01 to 2025-03-3159,065USD90
2024-10-01 to 2025-03-31118,130USD182
2024-01-01 to 2024-03-3159,064USD91
2023-10-01 to 2024-03-31118,129USD183

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-10-01 to 2025-03-31168,655USD182
2023-10-01 to 2024-03-31328,734USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-03-31-20,951,859USD
At 2024-09-30-20,417,118USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-01-01 to 2025-03-3121,554,704shares90
2024-10-01 to 2025-03-3118,730,773shares182
2024-01-01 to 2024-03-314,110,265shares91
2023-10-01 to 2024-03-313,596,027shares183

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-01-01 to 2025-03-3121,554,704shares90
2024-10-01 to 2025-03-3118,730,773shares182
2024-01-01 to 2024-03-314,110,265shares91
2023-10-01 to 2024-03-313,596,027shares183

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-01-01 to 2025-03-310USD/shares90
2024-10-01 to 2025-03-31-0.03USD/shares182
2024-01-01 to 2024-03-31-0.03USD/shares91
2023-10-01 to 2024-03-31-0.07USD/shares183

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-01-01 to 2025-03-310USD/shares90
2024-10-01 to 2025-03-31-0.03USD/shares182
2024-01-01 to 2024-03-31-0.03USD/shares91
2023-10-01 to 2024-03-31-0.07USD/shares183

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-113,349USD90
2024-10-01 to 2025-03-31-174,727USD182
2024-01-01 to 2024-03-31-101,071USD91
2023-10-01 to 2024-03-31-223,853USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-03-31151,749USD
At 2024-09-30143,351USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-03-315,867,880USD
At 2024-09-305,378,456USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-03-3133,703USD
At 2024-09-3029,669USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-03-31149,723USD
At 2024-09-3094,873USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-01-01 to 2025-03-31172,414USD90
2024-10-01 to 2025-03-31292,857USD182
2024-01-01 to 2024-03-31160,135USD91
2023-10-01 to 2024-03-31341,982USD183

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-01-01 to 2024-03-3140,133USD91
2023-10-01 to 2024-03-3187,661USD183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-03-3121,554,704shares
At 2024-09-305,258,235shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-03-3115,455,134USD
At 2024-09-3015,403,050USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2025-03-31-204,847USD
At 2024-09-30-204,847USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-03-311,752,511USD
At 2024-09-301,664,827USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-19,354USD90
2024-10-01 to 2025-03-31-534,739USD182
2024-01-01 to 2024-03-31-122,454USD91
2023-10-01 to 2024-03-31-267,387USD183

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2024-10-01 to 2025-03-31-534,739USD182
2023-10-01 to 2024-03-31-267,386USD183

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-19,354USD90
2024-10-01 to 2025-03-31-534,739USD182
2024-01-01 to 2024-03-31-122,454USD91
2023-10-01 to 2024-03-31-267,387USD183

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-01-01 to 2025-03-3113,348USD90
2024-10-01 to 2025-03-3126,665USD182
2024-01-01 to 2024-03-319,387USD91
2023-10-01 to 2024-03-3121,806USD183

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-01-01 to 2025-03-3122,329USD90
2024-10-01 to 2025-03-3147,681USD182
2024-01-01 to 2024-03-3117,044USD91
2023-10-01 to 2024-03-3134,828USD183

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2023-10-01 to 2024-03-31400,234USD183

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-10-01 to 2025-03-3154,847USD182
2023-10-01 to 2024-03-3139,723USD183

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-10-01 to 2025-03-314,034USD182
2023-10-01 to 2024-03-31124USD183

Inspect the source

Entity
REGEN BIOPHARMA, INC. / CIK 0001589150
Captured
2026-09-20T09:23:48.532Z
SEC response SHA-256
0bbe246b6080c7701ba978807745a4ba9de62971ab4db32e8d3e2fa2c4f26a87

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001589150.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))